SAN DIEGO, May 8, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that Primmune’s Senior Vice President & Chief Scientific Officer James Appleman, Ph.D., will present at the 4th STING & TLR-Targeting Therapies Summit being held in Boston, Massachusetts from May 9-11, 2023.
The oral presentation will cover the recent clinical progress of PRTX007, a systemically active, orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist and will evaluate how the unique pharmacology elicited by PRTX007 distinguishes Primmune’s lead candidate from other TLR7 agonists in human cellular models, in non-human primates, and in the clinical setting. The presentation at the Summit will also review how PRX034, the TLR7 agonist systemically delivered by PRTX007, has been shown to induce engagement of the innate and adaptive immune responses while avoiding systemic inflammation in healthy volunteers, and why PRTX007’s favorable profile is expected to correlate with efficacy in cancer therapy.
Presentation details:
Title: PRTX007, a Novel Orally Administered TLR7 Agonist Prodrug from Primmune Therapeutics for the Treatment of Cancer
Presenter: James Appleman, Ph.D.
Date and Time: Wednesday, May 10 at 10 a.m. ET
Location: Hilton Boston Back Bay
More information on the conference can be found here.
About PRTX007
PRTX007, Primmune’s lead clinical development candidate, is designed to provide well-tolerated, controlled, long-term stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 administration uniquely activates plasmacytoid dendritic cells (pDCs), leading to a systemic immune poly-IFN response without stimulating production of NF-κB-driven proinflammatory factors like IL-6, TNFα or IL-1β. Activated pDCs directly deliver interferons to target cells by paracrine transfer. Conceptually, this is equivalent to administering a therapeutically effective cocktail of all Type I/III IFNs while avoiding the associated side effects and adverse events. Furthermore, PRTX007 administration leads to systemic activation of anti-tumor effector CD8+ T cells and NK cells. PRTX007 is being rapidly advanced towards clinical trials for solid tumors in the advanced cancer setting and for clearing human papillomavirus-transformed pre-cancerous cervical lesions.
About Primmune Therapeutics
Primmune Therapeutics is a clinical-stage biotech harnessing the power of the innate immune system by developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for the treatment of solid tumors in the advanced cancer setting and for clearing human papillomavirus-transformed pre-cancerous cervical lesions. For more information, please visit https://www.primmunerx.com/.
Media Contact:
MacDougall Advisors
Karen Sharma
ksharma@macdougall.bio
781-235-3060